LONDON, Jan. 7, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
MediFocus: Future of Molecular Imaging
MediFocus: Future of Molecular Imaging
Summary
Molecular imaging is at the frontier of diagnostic imaging. It is a vast and multi-disciplinary field that consists of a range of techniques, allowing imaging of various organs and sites within the body with specific targeted probes. Molecular imaging can be defined as ''the visualization, characterization and measurement of biological processes at the molecular and cellular levels in human and other living systems''. Although sluggish economic growth has hindered the growth of the molecular imaging market right from its inception in the leading economies of the world such as in the United States and Europe, the market has attracted attention from both academia and manufacturers in recent years. The need for less invasive imaging techniques and more specific imaging probes has fuelled continued development and ever-changing market competition with molecular imaging.
GlobalData has released its medical device report, "MediFocus: Future of Molecular Imaging". The report offers a comprehensive analysis of the molecular imaging market, including new imaging techniques and late-stage imaging probes. Included within is an analysis of companies currently active in the field with their commercial positioning and portfolio assessment. The report identifies and evaluates key trends and advances shaping the global molecular imaging market, highlighting testimonials from top physicians around the world. The report provides insight into the market opportunities, barriers and drivers within the market for the benefit of new companies willing to enter this market in the near future. This report was built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of diagnostic imaging experts.
Scope
- An overview of the molecular imaging landscape
- Investigation of current and future market competition for molecular imaging
- Pipeline assessment with product profiles, SWOT analysis and commercial positioning
- Evaluation of technology trends in molecular imaging and physician perception
- Coverage of key market players with portfolio assessment and SWOT analysis
- Direct quotes from Key Opinion Leaders (KOL) currently using and developing molecular imaging probes
Reasons to buy
- Understand the trends shaping and driving the molecular imaging markets
- Drive revenues, formulate effective sales and marketing strategies, and gain in-depth understanding of the competitive landscape
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition
- Take a comprehensive look at the market's late-stage probe pipeline and identify promising, paradigm-shifting products
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth
- What's the next big thing in the global molecular imaging market? Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
3 Overview 19
3.1 What is Molecular Imaging? 19
3.2 What are Molecular Imaging Probes? 20
3.3 Growth of Molecular Imaging 21
3.4 Imaging Techniques 22
3.4.1 Overview 22
3.4.2 Positron Emission Tomography (PET) 24
3.4.3 Single Photon Emission Computed Tomography (SPECT) 30
3.4.4 Computed Tomography 32
3.4.5 Magnetic Resonance Imaging 33
3.4.6 Ultrasound Imaging 35
3.4.7 Other Emerging Techniques 37
3.5 Applications of MI 39
3.5.1 Overview 39
3.5.2 Oncology 39
3.5.3 Cardiology 41
3.5.4 Neurology 42
4 Unmet Needs Analysis 43
4.1 Overview 43
4.2 Radiation Exposure 43
4.3 Instrumentation Improvement 44
4.4 Lack of Multidisciplinary-Trained Professionals 45
4.5 Standardization 46
5 Market Opportunity Analysis 48
5.1 Probes for Image-Guided Surgery 48
5.2 Gallium-68 49
5.3 Low-Cost PET Systems 50
5.4 Molecular Imaging in Infectious Disease 52
5.5 Hybrid Imaging 53
5.6 Longer-Lived Isotopes 55
5.7 Role of Imaging Probes in Drug Development 56
6 Market Drivers and Barriers 58
6.1 Overview 58
6.2 Driver: Increased Prevalence of Diseases 58
6.3 Driver: Enthusiasm Surrounding Personalized Medicine 59
6.4 Driver: Hyperpolarized MRS with 13C Holds Promise 59
6.5 Driver: MI Applied to Drug Discovery and Development 60
6.6 Barrier: Regulatory Burden 61
6.7 Barrier: Cost 63
6.8 Barrier: Reimbursement 64
6.9 Barrier: Imaging Probe Production and Distribution Network 65
6.10 Barrier: Predicted 99mTc Shortage 67
6.11 Barrier: Reduced Hospital Budgets 68
6.12 Barrier: Limited Practical Value of Diagnostics in the Absence of Therapeutics 68
6.13 Barrier: Increased Consciousness Regarding Radiation Dose 71
7 Imaging Probes Assessment 73
7.1 Overview 73
7.2 Small Molecules 74
7.2.1 Overview 74
7.2.2 SWOT Analysis 75
7.2.3 [18F]Fluoro-2-deoxy-2-D-glucose ([18F]FDG) 75
7.2.4 3'-Deoxy-3'-[18F]fluorothymidine ([18F]FLT) 79
7.2.5 [18F]Fluoromisonidazole ([18F]FMISO) 82
7.2.6 1-(5-[18F]Fluoro-5-deoxy-?-D-arabinofuranosyl)-2-nitroimidazole ([18F]FAZA) 85
7.2.7 L-3,4-Dihydroxy-6-[18F]fluorophenylalanine ([18F]FDOPA) 88
7.2.8 [18F]Sodium flouride ([18F]NaF) 90
7.2.9 [11C]Acetate 93
7.2.10 N-Methyl-[11C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiasole ([11C]PiB) 96
7.3 Peptides 99
7.3.1 Overview 99
7.3.2 SWOT Analysis 100
7.4 Nanoparticles 100
7.4.1 Overview 100
7.4.2 Types of Nanoparticles for Molecular Imaging 101
7.4.3 SWOT Analysis 102
7.5 Engineered Proteins 103
7.5.1 Overview 103
7.5.2 SWOT Analysis 104
7.6 Aptamers 104
7.6.1 Overview 104
7.6.2 SWOT Analysis 105
8 Probes Pipeline Assessment 106
8.1 Overview 106
8.2 [18F]flurpiridaz (Lantheus Medical Imaging) 106
8.2.1 Overview 106
8.2.2 SWOT Analysis 107
8.3 NAV4694 (Navidea Biopharmaceuticals) 108
8.3.1 Overview 108
8.3.2 SWOT Analysis 109
8.4 [18F]flutemetamol (GE Healthcare) 109
8.4.1 Overview 109
8.4.2 SWOT Analysis 110
8.5 [18F]florbetaben (Piramal Imaging) 111
8.5.1 Overview 111
8.5.2 SWOT Analysis 111
8.6 REDECTANE (Wilex) 112
8.6.1 Overview 112
8.6.2 SWOT Analysis 113
9 Current and Future Players 114
9.1 Overview 114
9.2 Navidea Biopharmaceuticals 115
9.2.1 Overview 115
9.2.2 Portfolio Assessment 115
9.2.3 SWOT Analysis 118
9.3 Lantheus Medical Imaging 119
9.3.1 Overview 119
9.3.2 Portfolio Assessment 119
9.3.3 SWOT Analysis 121
9.4 Mallinckrodt Pharmaceuticals 122
9.4.1 Overview 122
9.4.2 Portfolio Assessment 122
9.4.3 SWOT Analysis 124
9.5 Avid Radiopharmaceuticals (Eli Lilly) 124
9.5.1 Overview 124
9.5.2 Portfolio Assessment 125
9.5.3 SWOT Analysis 127
9.6 Bracco Imaging 128
9.6.1 Overview 128
9.6.2 Portfolio Assessment 128
9.6.3 Product Recalls 129
9.6.4 SWOT Analysis 130
9.7 GE Healthcare 130
9.7.1 Overview 130
9.7.2 Portfolio Assessment 131
9.7.3 SWOT Analysis 133
9.8 Piramal Imaging 134
9.8.1 Overview 134
9.8.2 Portfolio Assessment 134
9.8.3 SWOT Analysis 135
9.9 Siemens 135
9.9.1 Overview 135
9.9.2 Portfolio Assessment 135
9.9.3 SWOT Analysis 137
9.10 Novelos Therapeutics 137
9.10.1 Overview 137
9.10.2 Portfolio Assessment 138
9.10.3 SWOT Analysis 139
9.11 Affibody 139
9.11.1 Overview 139
9.11.2 Portfolio Assessment 139
9.11.3 SWOT Analysis 140
9.12 Atreus Pharmaceuticals 141
9.12.1 Overview 141
9.12.2 Portfolio Assessment 141
9.12.3 SWOT Analysis 142
9.13 Kereos 142
9.13.1 Overview 142
9.13.2 Portfolio Assessment 142
9.13.3 SWOT Analysis 143
9.14 Progenics Pharmaceuticals 143
9.14.1 Overview 143
9.14.2 Portfolio Assessment 143
9.14.3 SWOT Analysis 145
9.15 FluoroPharma Medical 145
9.15.1 Overview 145
9.15.2 Portfolio Assessment 145
9.15.3 SWOT analysis 147
9.16 Wilex 147
9.16.1 Overview 147
9.16.2 Portfolio Assessment 148
9.16.3 SWOT analysis 149
9.17 Radiopharmaceutical Suppliers and Distributors 150
9.17.1 Supply-Chain Overview 150
9.17.2 Nordion 151
9.17.3 Positron 152
9.17.4 Cardinal Health 153
9.17.5 Advanced Accelerator Applications (AAA) 154
9.18 Other Companies 156
9.19 Key Deals, Partnerships, and Agreements 157
10 Appendix 158
10.1 Bibliography 158
10.2 Definitions 173
10.3 Abbreviations 174
10.4 Research Methodology 177
10.4.1 Overview 177
10.4.2 Coverage 177
10.4.3 Secondary Research 178
10.5 Physicians and Specialists Included in this Study 179
10.6 Primary Research 180
10.7 About the Authors 181
10.7.1 Analysts 181
10.7.2 Global Head of Healthcare 182
10.8 Disclaimer 183
1.1 List of Tables
Table 1: Desired Characteristics of an MI Probe 21
Table 2: PET SWOT Analysis, 2013 29
Table 3: SPECT SWOT Analysis, 2013 31
Table 4: CT SWOT Analysis, 2013 33
Table 5: MRI SWOT Analysis, 2013 35
Table 6: Ultrasound Imaging SWOT Analysis, 2013 37
Table 7: Applications of MI 39
Table 8: Role of Biomarkers in Drug Development 56
Table 9: Molecular Imaging – Drivers and Barriers, 2013 58
Table 10: Small Molecules SWOT Analysis, 2013 75
Table 11: Agent Profile of [18F]FDG 78
Table 12: [18F]FDG SWOT Analysis, 2013 78
Table 13: Agent Profile of [18F]FLT 81
Table 14: [18F]FLT SWOT Analysis, 2013 81
Table 15: Agent Profile of [18F]FMISO 84
Table 16: [18F]FMISO SWOT Analysis, 2013 84
Table 17: Agent Profile of [18F]FAZA 87
Table 18: [18F]FAZA SWOT Analysis, 2013 87
Table 19: Agent Profile of [18F]FDOPA 89
Table 20: [18F]FDOPA SWOT Analysis, 2013 90
Table 21: Agent Profile of [18F]NaF 92
Table 22: [18F]NaF SWOT Analysis, 2013 93
Table 23: Agent Profile of [11C]Acetate 95
Table 24: [11C]Acetate SWOT Analysis, 2013 96
Table 25: Agent Profile of [11C]PiB 98
Table 26: [11C]PiB SWOT Analysis, 2013 99
Table 27: Peptides SWOT Analysis, 2013 100
Table 28: Nanoparticles SWOT Analysis, 2013 102
Table 29: Engineered Proteins SWOT Analysis, 2013 104
Table 30: Aptamers SWOT Analysis, 2013 105
Table 31: [18F]flurpiridaz SWOT Analysis, 2013 107
Table 32: NAV4694 SWOT Analysis, 2013 109
Table 33: [18F]flutemetamol SWOT Analysis, 2013 110
Table 34: [18F]florbetaben SWOT Analysis, 2013 111
Table 35: REDECTANE SWOT Analysis, 2013 113
Table 36: Navidea Biopharmaceuticals' Portfolio Assessment, 2013 117
Table 37: Navidea Biopharmaceuticals SWOT Analysis, 2013 118
Table 38: Lantheus Medical Imaging Portfolio Assessment, 2013 120
Table 39: Lantheus Medical Imaging SWOT Analysis, 2013 121
Table 40: Mallinckrodt Pharmaceuticals Portfolio Assessment, 2013 123
Table 41: Mallinckrodt Pharmaceuticals SWOT Analysis, 2013 124
Table 42: Avid Radiopharmaceuticals Portfolio Assessment, 2013 126
Table 43: Avid Radiopharmaceuticals SWOT Analysis, 2013 127
Table 44: Bracco Imaging Portfolio Assessment, 2013 129
Table 45: Bracco Imaging SWOT Analysis, 2013 130
Table 46: GE Healthcare Portfolio Assessment, 2013 132
Table 47: GE Healthcare SWOT Analysis, 2013 133
Table 48: Piramal Imaging Portfolio Assessment, 2013 134
Table 49: Piramal Imaging SWOT Analysis, 2013 135
Table 50: Siemens Portfolio Assessment, 2013 136
Table 51: Siemens SWOT Analysis, 2013 137
Table 52: Novelos Therapeutics Portfolio Assessment, 2013 138
Table 53: Novelos Therapeutics SWOT Analysis, 2013 139
Table 54: Affibody Portfolio Assessment, 2013 140
Table 55: Affibody SWOT Analysis, 2013 140
Table 56: Atreus Pharmaceuticals Portfolio Assessment, 2013 141
Table 57: Atreus Pharmaceuticals SWOT Analysis, 2013 142
Table 58: Kereos Portfolio Assessment, 2013 142
Table 59: Kereos SWOT Analysis, 2013 143
Table 60: Progenics Portfolio Assessment, 2013 144
Table 61: Progenics Pharmaceuticals SWOT Analysis, 2013 145
Table 62: FluoroPharma Medical Portfolio Assessment, 2013 146
Table 63: FlouroPharma Medical SWOT Analysis, 2013 147
Table 64: Wilex Portfolio Assessment, 2013 148
Table 65: Wilex SWOT Analysis, 2013 149
Table 66: Nordion SWOT Analysis, 2013 151
Table 67: Positron SWOT Analysis, 2013 152
Table 68: Cardinal Health SWOT Analysis, 2013 154
Table 69: AAA SWOT Analysis, 2013 155
Table 70: Other Companies in the MI Market, 2013 156
Table 71: Other Key Events in the Molecular Imaging Market 157
1.2 List of Figures
Figure 1: Components of an MI Probe 20
Figure 2: Imaging Modalities 23
Figure 3: Siemens Biograph TruePoint PET/CT Scanner 26
Figure 4: GE Healthcare's Discovery NM/CT 670 SPECT/CT Scanner 31
Figure 5: Philips' Brilliance iCT CT Scanner 32
Figure 6: Toshiba Medical Systems' Vantage Titan 3T MRI Scanner 34
Figure 7: Hitachi Preirus Ultrasound Scanner 36
Figure 8: Imaging Applications in Drug Discovery and Development 57
Figure 9: Categories of Imaging Probes 73
Figure 10: Molecular Structure of [18F]FDG 76
Figure 11: Whole-Body PET Scan Using [18F]FDG 77
Figure 12: Molecular Structure of [18F]FLT 79
Figure 13: PET Scan Using [18F]FLT 80
Figure 14: Molecular Structure of [18F]FMISO 82
Figure 15: CT Scan (A), PET/CT Using [18F]FDG (B), and PET/CT Scan Using [18F]FMISO (C) 83
Figure 16: Molecular Structure of [18F]FAZA 85
Figure 17: [18F]FAZA-PET Scan 86
Figure 18: Molecular Structure of [18F]FDOPA 88
Figure 19: MRI Scan (Left) and [18F]FDOPA-PET Scan (Right) 89
Figure 20: Molecular structure of NaF 91
Figure 21: [18F]NaF-PET Bone Scan 92
Figure 22: Molecular Structure of [11C]Acetate 94
Figure 23: Comparison of Enhanced CT (A) with [18F]FDG-PET (B) and [11C]Acetate PET (C) 95
Figure 24: Molecular Structure of [11C]PiB 97
Figure 25: Comparison of [11C]PiB-PET Scans in Subjects with AD and Control Group 98
Figure 26: Supply Chain for Medical Isotopes 150
Companies Mentioned
Navidea Biopharmaceuticals
Lantheus Medical Imaging
Mallinckrodt Pharmaceuticals
Avid Radiopharmaceuticals (Eli Lilly)
Bracco Imaging
GE Healthcare
Piramal Imaging
Siemens
Novelos Therapeutics
Affibody
Atreus Pharmaceuticals
Kereos
Progenics Pharmac
Read the full report:
MediFocus: Future of Molecular Imaging
http://www.reportbuyer.com/pharma_healthcare/diagnostics/medifocus_future_molecular_imaging.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article